Time filter

Source Type

Zustovich F.,Instituto Oncologico Veneto IRCCS | Landi L.,Instituto Toscano Tumori | Lombardi G.,Instituto Toscano Tumori | Porta C.,Oncologia Medica IRCCS Policlinico S. Matteo | And 7 more authors.
Anticancer Research | Year: 2013

Background: Bevacizumab has provided encouraging results in relapsed glioblastoma multiforme (GBM). Pre-clinical and clinical investigations also showed that continuous low-dose temozolomide has some antiangiogenic activity. Based on this evidence, a phase II trial was designed to investigate an oral regimen of sorafenib, an oral multikinase inhibitor, and metronomic temozolomide for relapsed GBM. Patients and Methods: Forty-three patients (median age=60.0 years) naive for antiangiogenic agents received 400 mg sorafenib twice daily plus TMZ 40 mg/m2/day until disease progression. Results: Toxicity, mostly grade 1-2, was manageable. Grade 3-4 toxicities were hand-foot syndrome (n=4), hypertension (n=2), and fatigue (n=3). Five patients (12%) achieved partial response, 18 (43%) stable disease, 20 (48%) showed progression. The median time-to-progression was 3.2 months, 6-month progression-free survival was 26%, and median overall survival was 7.4 months. Conclusion: This combination of sorafenib and temozolomide was feasible and safe, showing some activity in patients with relapsed GBM.

Fontana A.,Dirigente Medico | Bona E.,Oncologia Universitaria | Falcone A.,University of Pisa
Salute e Societa | Year: 2014

Gender difference in cancer susceptibility, incidence, prognosis and aggressiveness have been observed for several types of tumors. Environmental and occupational exposures along with hormonal and immunological differences may be responsible for the disparity between males and females. Tumor immune surveillance, a recognized major physiological mechanism against cancer development and progression, is largely sex-dependent with a great activity in females respect to males. However, up today, no clinical trial evaluating new drugs or treatment strategy have been performed in a gender-specific manner and our knowledge derived from subgroup analysis, especially for what concerns women population. In this review, the authors point out gender differences in cancer epidemiology, response to treatments, toxicity and tumors related side effects. Colorectal and lung cancers will also described in order to underline the main gender differences. © FrancoAngeli.

Loading Oncologia Universitaria collaborators
Loading Oncologia Universitaria collaborators